Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ferrara

Showing results (21-30 of 143) with videos related to

Pageof 15
Sort By:
The Oncologist|February 12, 2020
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?Jacob J Adashek, Shumei Kato, Roberto Ferrara, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancerArsela Prelaj, Rebecca Tay, Roberto Ferrara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2022
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?Roberto Ferrara, Matteo Milani, Marina Chiara Garassino, et al.
Current Oncology Reports|April 17, 2020
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung CancerGiuseppe Lo Russo, Francesco Facchinetti, Marcello Tiseo, et al.
Cancer Immunology, Immunotherapy : CII|April 2, 2021
Myeloid cell heterogeneity in lung cancer: implication for immunotherapySabina Sangaletti, Roberto Ferrara, Claudio Tripodo, et al.
Transplantation|June 5, 2003
Cost and outcome analysis and cost determinants of liver transplantation in a European National Health Service hospitalFranco Filipponi, Roberto Pisati, Gianna Cavicchini, et al.
Journal of the American College of Cardiology|August 17, 2023
Long-Term Clinical Consequences of Right Ventricular Remodeling in Olympic Endurance AthletesAntonio Pelliccia, Roberto Ferrara, Silvia Prosperi, et al.
Expert Opinion on Biological Therapy|July 21, 2015
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectivesLorenzo Calvetti, Sara Pilotto, Luisa Carbognin, et al.
Clinical Therapeutics|November 9, 2004
Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst StudyPaolo Palatini, Francesca Dorigatti, Amedeo Mugellini, et al.
Translational Lung Cancer Research|July 23, 2021
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populationsRoberto Ferrara, Diego Signorelli, Claudia Proto, et al.
Pageof 15

Showing results (21-30 of 143) with videos related to

Sort By:
Pageof 15
The Oncologist|February 12, 2020
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?Jacob J Adashek, Shumei Kato, Roberto Ferrara, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancerArsela Prelaj, Rebecca Tay, Roberto Ferrara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2022
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?Roberto Ferrara, Matteo Milani, Marina Chiara Garassino, et al.
Current Oncology Reports|April 17, 2020
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung CancerGiuseppe Lo Russo, Francesco Facchinetti, Marcello Tiseo, et al.
Cancer Immunology, Immunotherapy : CII|April 2, 2021
Myeloid cell heterogeneity in lung cancer: implication for immunotherapySabina Sangaletti, Roberto Ferrara, Claudio Tripodo, et al.
Transplantation|June 5, 2003
Cost and outcome analysis and cost determinants of liver transplantation in a European National Health Service hospitalFranco Filipponi, Roberto Pisati, Gianna Cavicchini, et al.
Journal of the American College of Cardiology|August 17, 2023
Long-Term Clinical Consequences of Right Ventricular Remodeling in Olympic Endurance AthletesAntonio Pelliccia, Roberto Ferrara, Silvia Prosperi, et al.
Expert Opinion on Biological Therapy|July 21, 2015
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectivesLorenzo Calvetti, Sara Pilotto, Luisa Carbognin, et al.
Clinical Therapeutics|November 9, 2004
Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst StudyPaolo Palatini, Francesca Dorigatti, Amedeo Mugellini, et al.
Translational Lung Cancer Research|July 23, 2021
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populationsRoberto Ferrara, Diego Signorelli, Claudia Proto, et al.
Pageof 15